Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe  Shahram.

Slides:



Advertisements
Similar presentations
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Vaccination of Children following Allogeneic Stem Cell Transplantation
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Sabina Kersting, Leo F. Verdonck 
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.
Biology of Blood and Marrow Transplantation
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 
Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)  Tania.
Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival  Ashok Srinivasan, William Mitchell,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal.
Impact of Extremely Long Driving Distance on Distress and Physical Function in Hematopoietic Cell Transplant Recipients  Rahul Banerjee, Jean C. Yi, Navneet.
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Elucidating a Lipidomic and Metabolomic Signature of Gvhd in Recipients of Allogeneic Stem Cell Transplants  Daniel Contaifer, Catherine H. Roberts, Urszula.
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Amlodipine and Calcineurin Inhibitor Induced Nephrotoxicity Following Allogeneic Hematopoietic Stem Cell Transplant  Ryan R. Jensen, Regan Healy, Clyde.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
Infection Prevention - Visitors and the Best of Intentions
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?  Melhem.
Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA)  Samer.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Steven M. Trifilio, Judy Pi, Jayesh Mehta 
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant.
September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L
Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation
Symmetry Analysis of the T Cell Receptor Beta VJ Segment Usage in Allogeneic Stem Cell Transplantation  Jeremy A. Meier, Mohamed Fawaz, Masoud Manjili,
Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched.
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Blood and Marrow Transplant Handbook
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome  Peggy A. Wu,
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation 
IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation  Nikhil Dole, Nathan Luebbering, Nicholas.
Biology of Blood and Marrow Transplantation
Presentation transcript:

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe  Shahram Mori, Rushang D. Patel, Angela Boyd, Shayna Simon, Jan Nelson, Steven C. Goldstein  Biology of Blood and Marrow Transplantation  Volume 24, Issue 3, Pages S343-S344 (March 2018) DOI: 10.1016/j.bbmt.2017.12.408 Copyright © 2017 Terms and Conditions

Figure 1 Promacta response in Allogeneic and Autologous recipients Biology of Blood and Marrow Transplantation 2018 24, S343-S344DOI: (10.1016/j.bbmt.2017.12.408) Copyright © 2017 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.